Monte Rosa Therapeutics, Inc. Debt Securities, Available-for-sale, Realized Loss
Monte Rosa Therapeutics, Inc. (GLUE) reported Debt Securities, Available-for-sale, Realized Loss of $473.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. debt securities, available-for-sale, realized loss for the quarter ending 2026-06-30 was $473.00K, a 387.63% increase year-over-year.
- Monte Rosa Therapeutics, Inc. debt securities, available-for-sale, realized loss for the quarter ending 2026-03-31 was $974.00K, a 4538.10% increase year-over-year.
- Monte Rosa Therapeutics, Inc. debt securities, available-for-sale, realized loss for the quarter ending 2025-06-30 was $97.00K, a 708.33% increase year-over-year.
- Monte Rosa Therapeutics, Inc. debt securities, available-for-sale, realized loss for the quarter ending 2025-03-31 was $21.00K, a 425.00% increase year-over-year.
- Monte Rosa Therapeutics, Inc. debt securities, available-for-sale, realized loss for fiscal 2025 was -$47.00K.
- Monte Rosa Therapeutics, Inc. debt securities, available-for-sale, realized loss for fiscal 2024 was -$170.00K.
- Monte Rosa Therapeutics, Inc. debt securities, available-for-sale, realized loss for fiscal 2023 was -$397.00K, a 188.42% decline from fiscal 2022.
- Monte Rosa Therapeutics, Inc. debt securities, available-for-sale, realized loss for fiscal 2022 was $449.00K.
| Period end | Debt Securities, Available-for-sale, Realized Loss 3 month | Debt Securities, Available-for-sale, Realized Loss 6 month | Debt Securities, Available-for-sale, Realized Loss 9 month | Debt Securities, Available-for-sale, Realized Loss 12 month | Debt Securities, Available-for-sale, Realized Loss 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $473.00K 10-Q · filed 2026-08-06 | $1.45M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $974.00K 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | -$47.00K 10-K · filed 2026-03-17 | ||||
| 2025-06-30 | $97.00K 10-Q · filed 2026-08-06 | $118.00K 10-Q · filed 2026-08-06 | $243.00K derived: sum of 3 quarters · filed 2026-08-06 | -$68.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $21.00K 10-Q · filed 2026-05-07 | $146.00K derived: sum of 2 quarters · filed 2026-05-07 | -$165.00K derived: sum of 3 quarters · filed 2026-05-07 | -$153.00K derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $125.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$186.00K derived: sum of 2 quarters · filed 2026-03-17 | -$174.00K derived: sum of 3 quarters · filed 2026-03-17 | -$170.00K 10-K · filed 2026-03-17 | |
| 2024-09-30 | -$311.00K 10-Q · filed 2024-11-07 | -$299.00K derived: sum of 2 quarters · filed 2024-11-07 | -$295.00K 10-Q · filed 2024-11-07 | -$437.00K derived: sum of 4 quarters · filed 2025-05-08 | |
| 2024-06-30 | $12.00K 10-Q · filed 2024-08-08 | $16.00K 10-Q · filed 2024-08-08 | -$126.00K derived: sum of 3 quarters · filed 2025-05-08 | -$297.00K derived: sum of 4 quarters · filed 2025-05-08 | |
| 2024-03-31 | $4.00K 10-Q · filed 2025-05-08 | -$138.00K derived: sum of 2 quarters · filed 2025-05-08 | -$309.00K derived: sum of 3 quarters · filed 2025-05-08 | -$48.00K derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$142.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$313.00K derived: sum of 2 quarters · filed 2025-03-20 | -$52.00K derived: sum of 3 quarters · filed 2025-03-20 | -$397.00K 10-K · filed 2025-03-20 | |
| 2023-09-30 | -$171.00K 10-Q · filed 2024-11-07 | $90.00K derived: sum of 2 quarters · filed 2024-11-07 | -$255.00K 10-Q · filed 2024-11-07 | -$486.00K derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $261.00K 10-Q · filed 2024-08-08 | -$84.00K 10-Q · filed 2024-08-08 | -$315.00K derived: sum of 3 quarters · filed 2024-08-08 | -$139.00K derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$345.00K 10-Q · filed 2024-05-09 | -$576.00K derived: sum of 2 quarters · filed 2024-05-09 | -$400.00K derived: sum of 3 quarters · filed 2024-05-09 | -$42.00K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | -$231.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$55.00K derived: sum of 2 quarters · filed 2024-03-14 | $303.00K derived: sum of 3 quarters · filed 2024-03-14 | $449.00K 10-K · filed 2024-03-14 | -$449.00K 10-K · filed 2023-03-16 |
| 2022-09-30 | $176.00K 10-Q · filed 2023-11-09 | $534.00K derived: sum of 2 quarters · filed 2023-11-09 | $680.00K 10-Q · filed 2023-11-09 | $680.00K derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $358.00K 10-Q · filed 2023-08-10 | $504.00K 10-Q · filed 2023-08-10 | $504.00K derived: sum of 3 quarters · filed 2023-08-10 | $504.00K derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $146.00K 10-Q · filed 2023-05-11 | $146.00K derived: sum of 2 quarters · filed 2023-05-11 | $146.00K derived: sum of 3 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-16 | $0.00 10-K · filed 2023-03-16 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | |||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |